Jane Street
ACRV icon

Jane Street’s Acrivon Therapeutics ACRV Stock Holding History

Jane Street’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333K Sell
239,691
-102,380
-30% -$179K ﹤0.01% 8995
2025
Q4 		$824K Buy
342,071
+52,823
+18% +$115K ﹤0.01% 6552
2025
Q3 		$524K Sell
289,248
-22,581
-7% -$31.7K ﹤0.01% 7765
2025
Q2 		$371K Buy
+311,829
New +$428K ﹤0.01% 7471
2024
Q3 		– Sell
-30,714
Closed -$178K – 9488
2024
Q2 		$178K Buy
+30,714
New +$247K ﹤0.01% 8481

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street's ACRV Position: Q1 2026 in Review

Jane Street reduced its Acrivon Therapeutics (ACRV) stake by 30% in Q1 2026, selling an estimated $179K and leaving 239,691 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #8995.

Jane Street first reported a position in ACRV in Q2 2024 and has held it in 5 quarters since. The position peaked at $824K in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Jane Street held 239,691 shares of Acrivon Therapeutics worth $333K as of Q1 2026.
  • Jane Street sold 102,380 Acrivon Therapeutics shares in Q1 2026, an estimated $179K.
  • Acrivon Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8995 holding.
  • Jane Street first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Jane Street's Acrivon Therapeutics position peaked at $824K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.